Targeting Positive Regulatory Domain I-Binding Factor 1 and X Box-Binding Protein 1 Transcription Factors by Multiple Myeloma-Reactive CTL-Reference-Cited by-同舟云学术

Targeting Positive Regulatory Domain I-Binding Factor 1 and X Box-Binding Protein 1 Transcription Factors by Multiple Myeloma-Reactive CTL

Published:2005-07-07 Issue:2 Volume:175 Page:1301-1309
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J Immunol

Author:

Lotz Carina,Mutallib Sarah Abdel,Oehlrich Nicole,Liewer Ulrike,Ferreira Edite Antunes,Moos Marion,Hundemer Michael,Schneider Sandra,Strand Susanne,Huber Christoph,Goldschmidt Hartmut,Theobald Matthias

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference58 articles.

1. Transplantation for multiple myeloma: who, when, how often?

2. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-98 at European Group for Blood and Marrow Transplantation centres

3. Graft-versus-myeloma effect: proof of principle

4. Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Endoplasmic Reticulum Stress and Unfolded Protein Response in Inflammatory Bowel Disease;Inflammatory Bowel Diseases;2015-03

2. T cell-based targeted immunotherapies for patients with multiple myeloma;International Journal of Cancer;2014-09-19

3. Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOβ as a novel target for multiple myeloma;British Journal of Haematology;2013-08-30

4. Defining Multiple Myeloma as a Target for DNA Vaccines;Advances in Biology and Therapy of Multiple Myeloma;2012-11-01

5. Myeloma-Specific Multiple Peptides Able to Generate Cytotoxic T Lymphocytes: A Potential Therapeutic Application in Multiple Myeloma and Other Plasma Cell Disorders;Clinical Cancer Research;2012-07-02